Alkermes has reached an agreement to buy Avadel Pharma in a deal valued at up to $2.1 billion, claiming rights to an ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

An oversubscribed seed funding round will give Procyon the financial resources it needs to launch its first diagnostic – ...

Merck KGaA has become the third pharma company to reach an agreement with the Trump administration to cut the cost of some of ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...